Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enhabit, Inc. stock logo
EHAB
Enhabit
$10.50
+1.6%
$8.83
$6.85
$10.79
$523.08M1.61455,874 shs715,066 shs
InnovAge Holding Corp. stock logo
INNV
InnovAge
$3.99
-1.5%
$3.28
$2.60
$6.69
$538.70M0.452,732 shs43,709 shs
LifeMD, Inc. stock logo
LFMD
LifeMD
$12.15
+5.7%
$7.42
$3.99
$12.31
$522.20M2.22989,684 shs1.93 million shs
Exagen Inc. stock logo
XGN
Exagen
$6.97
-0.1%
$5.37
$1.71
$7.20
$148.67M1.5117,920 shs266,588 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enhabit, Inc. stock logo
EHAB
Enhabit
0.00%+2.78%+33.50%+25.45%+16.02%
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.00%+1.53%+33.89%+22.77%-1.24%
LifeMD, Inc. stock logo
LFMD
LifeMD
0.00%+5.38%+63.31%+130.99%+53.60%
Exagen Inc. stock logo
XGN
Exagen
0.00%+5.61%+13.52%+101.45%+264.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enhabit, Inc. stock logo
EHAB
Enhabit
2.1086 of 5 stars
1.05.00.00.03.50.82.5
InnovAge Holding Corp. stock logo
INNV
InnovAge
2.0646 of 5 stars
2.83.00.00.03.01.70.6
LifeMD, Inc. stock logo
LFMD
LifeMD
1.588 of 5 stars
1.54.00.00.04.01.70.6
Exagen Inc. stock logo
XGN
Exagen
3.7464 of 5 stars
2.53.00.04.52.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enhabit, Inc. stock logo
EHAB
Enhabit
2.00
Hold$8.50-19.05% Downside
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.50
Reduce$5.0025.31% Upside
LifeMD, Inc. stock logo
LFMD
LifeMD
3.00
Buy$11.00-9.47% Downside
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$7.507.60% Upside

Current Analyst Ratings Breakdown

Latest XGN, INNV, LFMD, and EHAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Exagen Inc. stock logo
XGN
Exagen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/15/2025
Exagen Inc. stock logo
XGN
Exagen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
5/13/2025
Exagen Inc. stock logo
XGN
Exagen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/7/2025
Exagen Inc. stock logo
XGN
Exagen
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/30/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
3/12/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $14.00
3/12/2025
Exagen Inc. stock logo
XGN
Exagen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/11/2025
LifeMD, Inc. stock logo
LFMD
LifeMD
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$15.00 ➝ $15.00
3/6/2025
Enhabit, Inc. stock logo
EHAB
Enhabit
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.03B0.52$3.23 per share3.25$13.90 per share0.76
InnovAge Holding Corp. stock logo
INNV
InnovAge
$831.68M0.65N/AN/A$1.90 per share2.10
LifeMD, Inc. stock logo
LFMD
LifeMD
$234.01M2.36N/AN/A$0.15 per share81.00
Exagen Inc. stock logo
XGN
Exagen
$56.72M2.62N/AN/A$1.33 per share5.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enhabit, Inc. stock logo
EHAB
Enhabit
-$80.50M-$2.77N/A36.21N/A-11.24%1.67%0.80%8/5/2025 (Estimated)
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$21.34M-$0.23N/A66.50N/A-3.19%-9.45%-4.84%N/A
LifeMD, Inc. stock logo
LFMD
LifeMD
-$20.60M-$0.34N/A101.25N/A-12.06%N/A-36.34%8/6/2025 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$23.69M-$0.84N/AN/AN/A-30.36%-92.58%-33.74%8/4/2025 (Estimated)

Latest XGN, INNV, LFMD, and EHAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million
5/7/2025Q1 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.07$0.10+$0.03$0.35$266.11 million$259.90 million
5/6/2025Q3 2025
InnovAge Holding Corp. stock logo
INNV
InnovAge
-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million
5/6/2025Q1 2025
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04$0.01+$0.05$0.01$62.47 million$65.70 million
3/10/2025Q4 2024
LifeMD, Inc. stock logo
LFMD
LifeMD
-$0.04-$0.02+$0.02-$0.02$57.43 million$64.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
N/AN/AN/AN/AN/A
LifeMD, Inc. stock logo
LFMD
LifeMD
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enhabit, Inc. stock logo
EHAB
Enhabit
0.85
1.46
1.46
InnovAge Holding Corp. stock logo
INNV
InnovAge
0.27
1.16
1.16
LifeMD, Inc. stock logo
LFMD
LifeMD
N/A
0.83
0.78
Exagen Inc. stock logo
XGN
Exagen
1.54
4.05
4.05

Institutional Ownership

CompanyInstitutional Ownership
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A
InnovAge Holding Corp. stock logo
INNV
InnovAge
12.26%
LifeMD, Inc. stock logo
LFMD
LifeMD
35.52%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
InnovAge Holding Corp. stock logo
INNV
InnovAge
1.40%
LifeMD, Inc. stock logo
LFMD
LifeMD
15.97%
Exagen Inc. stock logo
XGN
Exagen
12.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,90050.64 million49.33 millionOptionable
InnovAge Holding Corp. stock logo
INNV
InnovAge
2,000135.01 million133.35 millionOptionable
LifeMD, Inc. stock logo
LFMD
LifeMD
23045.45 million36.40 millionOptionable
Exagen Inc. stock logo
XGN
Exagen
22021.30 million13.03 millionOptionable

Recent News About These Companies

Short Interest in Exagen Inc. (NASDAQ:XGN) Expands By 59.4%
Exagen Inc. stock logo
Exagen Inc. (NASDAQ:XGN) Short Interest Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enhabit stock logo

Enhabit NYSE:EHAB

$10.50 +0.17 (+1.65%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$10.48 -0.02 (-0.19%)
As of 05/30/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

InnovAge stock logo

InnovAge NASDAQ:INNV

$3.99 -0.06 (-1.48%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$4.17 +0.18 (+4.49%)
As of 05/30/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

LifeMD stock logo

LifeMD NASDAQ:LFMD

$12.15 +0.66 (+5.74%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$12.18 +0.04 (+0.29%)
As of 05/30/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

Exagen stock logo

Exagen NASDAQ:XGN

$6.97 -0.01 (-0.14%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$6.80 -0.17 (-2.37%)
As of 05/30/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.